In a first, Re­gen­eron's an­ti­body cock­tail re­duces deaths for a sub­group of hos­pi­tal­ized Covid-19 pa­tients

Sci­en­tists have come up with the first ev­i­dence that Re­gen­eron’s an­ti­body cock­tail, which has so far on­ly been au­tho­rized for the out­pa­tient set­ting, may re­duce deaths of hos­pi­tal­ized Covid-19 pa­tients — al­beit on­ly a sub­set.

The com­bi­na­tion of casiriv­imab and imde­vimab is the sub­ject of the lat­est da­ta cut from RE­COV­ERY, the large-scale UK-based tri­al test­ing a va­ri­ety of po­ten­tial treat­ments. In to­tal, 9,785 pa­tients hos­pi­tal­ized with Covid-19 were en­rolled in this arm of the study and were ran­dom­ly as­signed to re­ceive ei­ther usu­al care plus the in­tra­venous com­bo or usu­al care alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER